Search
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
VXA-CoV2-1
go.drugbank.com/drugs/DB16433InvestigationalThis oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell … responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498].
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalIt is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine
go.drugbank.com/drugs/DB08667ExperimentalThis compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide
go.drugbank.com/drugs/DB06941ExperimentalThis compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Cinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
NBI-6024
go.drugbank.com/drugs/DB05819InvestigationalNBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
DDP733
go.drugbank.com/drugs/DB05049InvestigationalSerotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract).
Ivarmacitinib
go.drugbank.com/drugs/DB16756InvestigationalWhile ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis
Docosanol
go.drugbank.com/drugs/DB00632ApprovedDocosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid e...